UBS cuts AnaptysBio stock price target to $60 on business spinoff

UBS cut AnaptysBio’s price target to $60 from $90 but kept a Buy rating, while other recent targets remain bullish, including Piper Sandler at $95 and H.C. Wainwright at $66. The company has completed the spin-off of its biopharma business into First Tracks Biotherapeutics and will now operate as a royalty-focused entity centered on Jemperli and imsidolimab, with about $140-$145 million in net cash. UBS said Jemperli reached a $1.4 billion run rate exiting 2025, supporting a higher valuation despite the lower target.

Analysis

ANAB is transitioning from a development-stage biotech to a royalty monetization vehicle, which should materially compress the range of outcomes: lower operating risk, but also a lower ceiling unless the royalty asset can compound faster than the market expects. The key second-order effect is that the stock may start trading less like biotech and more like a small-cap yield/security with a duration-like cash flow stream; that tends to attract a different shareholder base and can support multiple expansion if the company actually behaves like capital-return machinery.

The main driver is now concentration risk. A single royalty stream tied to Jemperli becomes the entire equity story, so any incremental adoption inflection or label expansion can move the stock disproportionately, while any commercial disappointment will be punished harder because there is no pipeline diversification left to cushion it. That makes the next 2-4 quarters about estimating whether royalty growth can offset the inevitable decline in the “spinco” novelty premium and whether management can credibly translate net cash into accretive capital returns.

For GSK, the spillover is modest but directionally positive: if Jemperli keeps scaling, the royalty obligation is a manageable economic drag relative to the value created by greater product traction. The sharper implication is for other royalty-heavy biotech assets: investors may re-rate them if ANAB begins to trade on cash flow yield rather than headline biotech multiples. Conversely, if ANAB fails to hold above a low-teens EV/royalty framework, it would signal the market still demands pipeline optionality even for so-called pure plays.

The contrarian point is that the move may be partially over-earned already: the stock has already priced in a lot of the “clean-up story,” so the next leg likely requires visible royalty acceleration, not just simplification. Without a near-term capital-return catalyst, the shares can drift as event-driven holders rotate out after the corporate action settles.

Key Decisions for Investors

• Long ANAB on a 3-6 month horizon only on pullbacks toward implied royalty value; target a re-rate toward an 8x-10x cash-flow multiple, but cut if Jemperli growth decelerates for two consecutive quarters.
• Use a covered-call structure on ANAB if holding into the April 2026 distribution event; monetize elevated event-driven volatility while limiting upside bleed from post-spin de-rating.
• Pair trade: long ANAB / short a basket of lower-quality royalty or single-asset biotech names that still trade on pipeline optionality; the thesis is that ANAB becomes the cleaner cash-return story first.
• For GSK, treat this as a small supportive data point rather than a core driver; any long position should be sized around the incremental royalty burden being manageable, not a valuation catalyst.
• Monitor for a shareholder-return announcement within the next 1-2 quarters; if no buyback/dividend framework emerges, expect the market to reduce the multiple despite the simplification.